Johnson & Johnson vs Pacific Biosciences of Californ — Stock Comparison
Johnson & Johnson (JNJ) and Pacific Biosciences of Californ (PACB) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson holds a significant lead over Pacific Biosciences of Californ on Q·Score (7.1 vs 4.5 out of 10), led by Quality (9.3 vs 0.2) and Sentiment (6.9 vs 5.6). Pacific Biosciences of Californ scores higher on Growth, reflecting stronger revenue and earnings momentum. Analyst consensus targets imply greater upside for PACB (+75.6%) than for JNJ (+10.7%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Consensus analyst target of $2.46 is 76% above current price.
⚠ currently unprofitable (-80% margin).
Analyst Consensus
Fundamentals
Frequently Asked Questions
JNJ vs PACB: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 7.1/10 versus Pacific Biosciences of Californ (PACB) at 4.5/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: JNJ or PACB?
Pacific Biosciences of Californ (PACB) scores higher on Growth (5.8/10 vs 5.1/10). Johnson & Johnson reports revenue growth (9.9% YoY) while Pacific Biosciences of Californ reports (0.1% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is JNJ or PACB more attractively valued?
Johnson & Johnson (JNJ) scores higher on Valuation (7.3/10 vs 6.3/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about JNJ vs PACB?
There are 23 analysts covering JNJ with a consensus price target of $252.87, and 6 analysts covering PACB with a consensus target of $2.46. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: JNJ or PACB?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 0.2/10). Net profit margin: JNJ at 21.8%, PACB at -80.3%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: JNJ or PACB?
Johnson & Johnson (JNJ) scores higher on Financial Health (6.5/10 vs 5.7/10). Market beta: JNJ at 0.26, PACB at 2.32. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of JNJ and PACB?
Johnson & Johnson (JNJ) has a market capitalisation of $549.8B, while Pacific Biosciences of Californ (PACB) has a market cap of $435M. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do JNJ or PACB pay dividends?
JNJ pays a dividend yield of 2.35%, while PACB does not currently pay a dividend. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →